Paper Details
- Home
- Paper Details
Long-term thionamide antithyroid treatment of Graves' disease.
Author: AbdiHengameh, AmouzegarAtieh, AziziFereidoun, Habibi MoeiniAli Siamak
Original Abstract of the Article :
Thionamide antithyroid drugs (ATD) are the treatment of choice for Graves' hyperthyroidism. The major drawback of ATD treatment for 1-2 years is the relapse of hyperthyroidism in about 50% of patients. Recently, it has been shown that ATD treatment for more than five years is accompanied by long-ter...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1016/j.beem.2022.101631
データ提供:米国国立医学図書館(NLM)
Long-Term Thionamide Antithyroid Treatment: A Oasis in the Desert of Graves' Disease
Graves' disease, a formidable foe in the desert of thyroid disorders, is often treated with thionamide antithyroid drugs (ATDs). The treatment landscape, however, can be complex and require careful navigation. This research explores the long-term efficacy and safety of ATD treatment, offering a glimmer of hope for patients grappling with this challenging condition. The study reviewed existing evidence on long-term ATD therapy, highlighting the potential for long-term remission in a significant portion of patients. The authors emphasize the favorable outcomes associated with long-term ATD treatment, particularly when compared to radioactive iodine therapy. This research offers valuable insights into the long-term management of Graves' disease, illuminating a path towards sustained remission.
A Desert of Relapses
Traditional ATD treatment for Graves' disease is often plagued by a high rate of relapse, with approximately 50% of patients experiencing a return of hyperthyroidism after just one to two years. This research, however, offers a promising alternative, revealing that long-term ATD treatment exceeding five years can significantly reduce the risk of relapse, providing a more enduring oasis of stability for patients.
A Desert of Uncertainties
The desert of medical treatments is often filled with uncertainties, and the decision to pursue long-term ATD therapy should be made in consultation with a healthcare professional. Patients should weigh the potential benefits of long-term remission against the potential risks and side effects of the medication.
Dr.Camel's Conclusion
Long-term ATD treatment offers a potential path to sustained remission for patients with Graves' disease. It is like finding an oasis in the vast desert of thyroid disorders, providing a source of relief and stability for many. However, navigating this treatment landscape requires careful consideration and close monitoring by a healthcare professional.
Date :
- Date Completed 2023-03-21
- Date Revised 2023-03-27
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.